XNCR Xencor Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XNCR

Price (delayed)

$21.65

Market cap

$1.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.19

Enterprise value

$1.39B

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights
XNCR's revenue has surged by 65% year-on-year but it is down by 3.7% since the previous quarter
The gross profit has soared by 65% YoY but it has decreased by 3.7% from the previous quarter
Xencor's debt has surged by 51% YoY and by 7% QoQ
XNCR's quick ratio is down by 26% year-on-year and by 3.8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xencor.com
Peers: AMGN MGNX MRK ABBV

Key stats

What are the main financial stats of XNCR
Market
Shares outstanding
61.66M
Market cap
$1.33B
Enterprise value
$1.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.16
Price to sales (P/S)
8.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.59
Earnings
Revenue
$162.18M
EBIT
-$127.55M
EBITDA
-$115.26M
Free cash flow
$52.67M
Per share
EPS
-$2.19
Free cash flow per share
$0.86
Book value per share
$10.02
Revenue per share
$2.65
TBVPS
$14.14
Balance sheet
Total assets
$884.26M
Total liabilities
$272.07M
Debt
$89.33M
Equity
$612.53M
Working capital
$482.85M
Liquidity
Debt to equity
0.15
Current ratio
7.08
Quick ratio
6.88
Net debt/EBITDA
-0.5
Margins
EBITDA margin
-71.1%
Gross margin
100%
Net margin
-82.2%
Operating margin
-84.6%
Efficiency
Return on assets
-15.7%
Return on equity
-20.3%
Return on invested capital
-16.1%
Return on capital employed
-15.8%
Return on sales
-78.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XNCR stock price

How has the Xencor stock price performed over time
Intraday
1.79%
1 week
13.11%
1 month
11.43%
1 year
-10.8%
YTD
1.98%
QTD
14.37%

Financial performance

How have Xencor's revenue and profit performed over time
Revenue
$162.18M
Gross profit
$162.18M
Operating income
-$137.13M
Net income
-$133.36M
Gross margin
100%
Net margin
-82.2%
XNCR's revenue has surged by 65% year-on-year but it is down by 3.7% since the previous quarter
The gross profit has soared by 65% YoY but it has decreased by 3.7% from the previous quarter
XNCR's operating margin has surged by 51% year-on-year but it is down by 2.7% since the previous quarter
Xencor's net margin has increased by 42% YoY but it has decreased by 10% QoQ

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation
XNCR P/E details
P/E
N/A
P/B
2.16
P/S
8.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.59
The EPS has increased by 7% YoY but it has decreased by 5% QoQ
XNCR's P/B is 24% below its 5-year quarterly average of 2.8 but 6% above its last 4 quarters average of 2.0
XNCR's equity is down by 10% year-on-year and by 8% since the previous quarter
XNCR's revenue has surged by 65% year-on-year but it is down by 3.7% since the previous quarter
XNCR's P/S is 39% below its 5-year quarterly average of 13.2 and 15% below its last 4 quarters average of 9.4

Efficiency

How efficient is Xencor business performance
The ROS has increased by 44% YoY but it has decreased by 10% QoQ
The ROIC has grown by 15% YoY
XNCR's ROE is down by 9% from the previous quarter and by 4.6% YoY
The ROA has grown by 6% YoY but it has contracted by 3.3% from the previous quarter

Dividends

What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time
XNCR's total liabilities has surged by 127% year-on-year but it is down by 4.1% since the previous quarter
The company's current ratio fell by 27% YoY and by 3.8% QoQ
Xencor's debt is 85% lower than its equity
The debt to equity has soared by 67% YoY and by 25% from the previous quarter
Xencor's debt has surged by 51% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.